Lysosomal Lipid Dysregulation in Parkinson's Disease: Genetic and Medication Effects in CSF Metabolomics

Parkinson's disease (PD) is a heterogeneous neurodegenerative disorder with clinical and molecular diversity across genetic and sporadic forms. Cerebrospinal fluid (CSF) metabolomics provides direct access to brain biochemistry, enabling investigation of metabolic pathways disrupted in disease. This analysis aims to identify metabolic signatures distinguishing sporadic PD (sPD), LRRK2-PD, and GBA-PD, and reveal shared and distinct biochemical processes underlying disease pathogenesis.